RPTXRepare Therapeutics Inc.

Nasdaq reparerx.com


$ 3.32 $ -0.10 (-2.94 %)    

Wednesday, 22-May-2024 15:59:49 EDT
QQQ $ 454.82 $ -0.09 (-0.02 %)
DIA $ 398.57 $ -2.12 (-0.53 %)
SPY $ 530.36 $ -1.53 (-0.29 %)
TLT $ 91.26 $ 0.11 (0.12 %)
GLD $ 225.37 $ -4.12 (-1.84 %)
$ 3.3
$ 3.36
$ 0.00 x 0
$ 0.00 x 0
$ 3.26 - $ 3.37
$ 2.98 - $ 13.85
210,103
na
145.28M
$ 0.84
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-07-2024 03-31-2024 10-Q
2 02-28-2024 12-31-2023 10-K
3 11-09-2023 09-30-2023 10-Q
4 08-09-2023 06-30-2023 10-Q
5 05-09-2023 03-31-2023 10-Q
6 02-28-2023 12-31-2022 10-K
7 11-09-2022 09-30-2022 10-Q
8 08-04-2022 06-30-2022 10-Q
9 05-05-2022 03-31-2022 10-Q
10 03-01-2022 12-31-2021 10-K
11 11-10-2021 09-30-2021 10-Q
12 08-12-2021 06-30-2021 10-Q
13 05-13-2021 03-31-2021 10-Q
14 03-04-2021 12-31-2020 10-K
15 11-12-2020 09-30-2020 10-Q
16 08-13-2020 06-30-2020 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 repare-therapeutics-q1-eps-030-beats-002-estimate-sales-5240m-beat-3840m-estimate

Repare Therapeutics (NASDAQ:RPTX) reported quarterly earnings of $0.30 per share which beat the analyst consensus estimate of $...

 roches-lymphoma-drug-with-chemo-extends-survival-in-pretreated-patients

Roche study results show prolonged survival in R/R diffuse large B-cell lymphoma patients treated with Columvi (glofitamab) + G...

 hc-wainwright--co-reiterates-buy-on-repare-therapeutics-maintains-10-price-target

HC Wainwright & Co. analyst Robert Burns reiterates Repare Therapeutics (NASDAQ:RPTX) with a Buy and maintains $10 price...

 hc-wainwright--co-reiterates-buy-on-repare-therapeutics-maintains-10-price-target

HC Wainwright & Co. analyst Robert Burns reiterates Repare Therapeutics (NASDAQ:RPTX) with a Buy and maintains $10 price...

 hc-wainwright--co-maintains-buy-on-repare-therapeutics-lowers-price-target-to-10

HC Wainwright & Co. analyst Robert Burns maintains Repare Therapeutics (NASDAQ:RPTX) with a Buy and lowers the price tar...

 roche-terminates-cancer-drug-pact-with-repare-therapeutics-its-second-walkout-within-a-month

Repare Therapeutics regains global rights to camonsertib (RP-3500) after terminating collaboration with Roche. $40M milestone a...

Core News & Articles

Roche notified Repare that, effective May 7, 2024, it is terminating its worldwide license and collaboration agreement for the ...

 debiopharm-partners-with-repare-therapeutics-to-explore-synthetic-lethal-combination-of-pkmyt1-and-wee1-inhibition-in-cancer

Collaborative clinical study will investigate a novel combination of Debio 0123, Debiopharm's potent, brain penetrant inhib...

 hc-wainwright--co-reiterates-buy-on-repare-therapeutics-maintains-25-price-target

HC Wainwright & Co. analyst Robert Burns reiterates Repare Therapeutics (NASDAQ:RPTX) with a Buy and maintains $25 price...

 repare-therapeutics-q3-eps-045-beats-086-estimate-sales-216m-miss-631m-estimate

Repare Therapeutics (NASDAQ:RPTX) reported quarterly losses of $(0.45) per share which beat the analyst consensus estimate of $...

Core News & Articles

The Dow Jones closed higher by over 200 points on Friday. When insiders purchase or sell shares, it indicates their confidence ...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION